Mind Medicine (MindMed) (MNMD) Projected to Post Quarterly Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.08). During the same period in the prior year, the business posted ($0.59) earnings per share. On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock traded down $0.13 during trading hours on Tuesday, hitting $6.42. 250,225 shares of the company traded hands, compared to its average volume of 1,734,653. The firm's 50-day simple moving average is $6.12 and its two-hundred day simple moving average is $6.95. The firm has a market cap of $483.94 million, a P/E ratio of -2.85 and a beta of 2.52. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $10.44. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 21,208 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares in the company, valued at $5,773,187.44. This represents a 2.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Daniel Karlin sold 6,836 shares of Mind Medicine (MindMed) stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the transaction, the insider now owns 446,177 shares in the company, valued at $3,007,232.98. This trade represents a 1.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,391 shares of company stock worth $204,835. Insiders own 2.26% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Robert W. Baird lowered their price objective on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They set an "outperform" rating and a $23.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $25.11.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.